Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer
Yuki Kohada1,2, Yasuhiro Kaiho1, Kazuya Takeda3
1Division of Urology Faculty of Medicine Tohoku Medical and Pharmaceutical University Sendai Japan.
Introduction:
The present study showed the involvement of immunosuppressive myeloid-derived suppressor cells during the disease progression in a 69-year-old man with a prostate cancer.
Case Presentation:
The patient with metastatic PC (cT4N1M1ab) was initially treated with primary androgen deprivation therapy for 5 months and then chemotherapy with docetaxel, but he expired at the 8th month. In order to investigate whether myeloid-derived suppressor cells are implicated in the cancer exacerbation during androgen deprivation therapy, we assessed the long-term changes in peripheral blood myeloid-derived suppressor cell fractions by using flow cytometry. While prostate-specific antigen levels decreased after androgen deprivation therapy, the population of each myeloid-derived suppressor cell subsets increased during disease deterioration.
Conclusion:
Increase in myeloid-derived suppressor cells populations was correlated with prostate cancer progression.
Insights
Immune cells called myeloid-derived suppressor cells increased as prostate cancer worsened. This suggests their role in disease progression during treatment.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Prostate cancer (PC) is a significant health concern.
- Understanding immune cell involvement in PC progression is crucial.
- This study investigates myeloid-derived suppressor cells (MDSCs) in advanced PC.
Observation:
- A patient with metastatic PC received androgen deprivation therapy and chemotherapy.
- Peripheral blood MDSC fractions were monitored using flow cytometry.
- MDSC populations increased during disease deterioration despite initial PSA reduction.
Findings:
- Increased myeloid-derived suppressor cell populations correlated with prostate cancer progression.
- MDSCs may play a role in cancer exacerbation during treatment.
Implications:
- Targeting MDSCs could be a potential therapeutic strategy for prostate cancer.
- Further research into the MDSC-PC interaction is warranted.
